Cancer Research and Treatment

Original Articles

Survey of Medical Oncology Status in Korea (SOMOS-K): A National Survey of Medical Oncologists in the Korean Association for Clinical Oncology (KACO): Do Yeun Kim, Yun Gyoo Lee, Bong-Seog Kim; Cancer Res Treat. 2017;49(3):588-594. Published online September 23, 2016; DOI: https://doi.org/10.4143/crt.2016.313

Purpose
This study was conducted to investigate the current role of medical oncologists in cancer care with a focus on increasing the recognition of medical oncology as an independent specialty.
Materials and Methods
Questionnaires modified from the Medical Oncology Status in Europe Survey dealing with oncology structure, resources, research, and patterns of care given by medical oncologists were selected. Several modifications were made to the questionnaire after feedback from the insurance and policy committee of the Korean Association for Clinical Oncology (KACO). The online survey was then sent to KACO members.
Results
A total of 214 medical oncologists (45.8% of the total inquiries), including 71 directors of medical oncology institutions, took the survey. Most institutions had various resources, including a medical oncology department (94.1%) and a department of radiation oncology (82.4%). There was an average of four medical oncologists at each institution. Medical oncologists were involved in various treatments from diagnosis to end-of-life care. They were also chemotherapy providers from a wide range of institutions that treated many types of solid cancers. In addition, 86.2% of the institutions conducted research.
Conclusion
This is the first national survey in Korea to show that medical oncologists are involved in a wide range of cancer treatments and care. This survey emphasizes the contributions and proper roles of medical oncologists in the evolving health care environment in Korea.

Citations

Citations to this article as recorded by

Current status of medical oncology in Japan and changes over the most recent 7-year period: results of a questionnaire sent to designated cancer care hospitals
Makoto Arai, Izumi Ohno, Koji Takahashi, Meng Meng Fan, Akinobu Tawada, Chikashi Ishioka, Yuichi Takiguchi
Japanese Journal of Clinical Oncology.2021; 51(11): 1622. CrossRef
Practice patterns of multidisciplinary team meetings in Korean cancer care and patient satisfaction with this approach
Chi Hoon Maeng, Hee Kyung Ahn, Sung Yong Oh, Seungtaek Lim, Bong-Seog Kim, Do Yeun Kim
The Korean Journal of Internal Medicine.2020; 35(1): 205. CrossRef
Surrogate decision making of chemotherapy consent: do we really provide informed consent of chemotherapy for patients?
Jung Hye Kwon, Sun Kyung Baek, Bong-Seog Kim, Su-Jin Koh, Hee Kyung Ahn, Joo Han Lim, Chiyeon Lim, Do Yeun Kim
The Korean Journal of Internal Medicine.2019; 34(3): 626. CrossRef

10,022 View
198 Download
4 Web of Science
3 Crossref

Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors: Do-Youn Oh, Tae-Min Kim, Sae-Won Han, Dong-Yeop Shin, Yun Gyoo Lee, Keun-Wook Lee, Jee Hyun Kim, Tae-You Kim, In-Jin Jang, Jong-Seok Lee, Yung-Jue Bang; Cancer Res Treat. 2016;48(1):28-36. Published online February 23, 2015; DOI: https://doi.org/10.4143/crt.2014.258

Abstract PDF PubReader ePub

Purpose
CKD-516 is a newly developed vascular disrupting agent. This phase I dose-escalation study of CKD-516 was conducted to determine maximum-tolerated dose (MTD), safety, pharmacokinetics, and preliminary antitumor efficacy in patients with advanced solid tumors. Materials and Methods Patients received CKD-516 intravenously on D1 and D8 every 3 weeks, in a standard 3+3 design. Safety was evaluated by National Cancer Institute Common Terminology Criteria for Adverse Events ver. 4.02 and response was assessed by Response Evaluation Criteria in Solid Tumor ver. 1.1.
Results
Twenty-three patients were treated with CKD-516 at seven dosing levels: 1 mg/m2/day (n=3), 2 mg/m2/day (n=3), 3.3 mg/m2/day (n=3), 5 mg/m2/day (n=3), 7 mg/m2/day (n=3), 9 mg/m2/day (n=6), and 12 mg/m2/day (n=2). Mean age was 54 and 56.5% of patients were male. Two dose-limiting toxicities, which were both grade 3 hypertension, were observed in two patients at 12 mg/m2/day. The MTD was determined as 12 mg/m2/day. Most common adverse events were gastrointestinal adverse events (diarrhea, 34.8% [30.4% grade 1/2, 13.0% grade 3]; nausea, 21.7% [all grade 1/2]; vomiting, 21.7% [all grade 1/2]), myalgia (17.4%, all grade 1/2), and abdominal pain (21.7% [21.7% grade 1/2, 4.3% grade 3]). The pharmacokinetic study showed the dose-linearity of all dosing levels. Among 23 patients, six patients (26.1%) showed stable disease. Median progression-free survival was 39 days (95% confidence interval, 37 to 41 days). Conclusion This study demonstrates feasibility of CKD-516, novel vascular disrupting agent, in patients with advanced solid tumor. MTD of CKD-516 was defined as 12 mg/m2/day on D1 and D8 every 3 weeks.

Citations

Citations to this article as recorded by

First-in-human phase 1 study of an orally bioavailable vascular-disrupting agent DX1002 in patients with advanced solid tumors
Xiao-Li Wei, Hao-Xiang Wu, Dan-Yun Ruan, Feng Wang, Li Xu, Yu-Hong Li, Yu-Xiang Ma, Zhi-Qiang Wang, Yun-Peng Yang, Liang-Wei Tang, Bao-Lin Chen, Zhi-Quan Yong, Rui-Hua Xu, Hong-Yun Zhao
Cell Reports Medicine.2025; 6(2): 101969. CrossRef
Natural‐Product‐Inspired Discovery of Trimethoxyphenyl‐1,2,4‐triazolosulfonamides as Potent Tubulin Polymerization Inhibitors
Vajja Krishna Rao, Anvesh Ashtam, Dulal Panda, Sankar K. Guchhait
ChemMedChem.2024;[Epub] CrossRef
Thiazole, Isatin and Phthalimide Derivatives Tested in vivo against Cancer Models: A Literature Review of the Last Six Years
Aline Ferreira Pinto, Janine Siqueira Nunes, José Eduardo Severino Martins, Amanda Calazans Leal, Carla Cauanny Vieira Costa Silva, Anderson José Firmino Santos da Silva, Daiane Santiago da Cruz Olímpio, Elineide Tayse Noberto da Silva, Thiers Araújo Camp
Current Medicinal Chemistry.2024; 31(20): 2991. CrossRef
CKD-516 potentiates the anti-cancer activity of docetaxel against epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer
Soo Jin Kim, Kyunghyeon Lee, Jaewoo Park, Miso Park, U. Ji Kim, Se-mi Kim, Keun Ho Ryu, Keon Wook Kang
Toxicological Research.2023; 39(1): 61. CrossRef
Virulence-attenuated Salmonella engineered to secrete immunomodulators reduce tumour growth and increase survival in an autochthonous mouse model of breast cancer
Lance B. Augustin, Liming Milbauer, Sara E. Hastings, Arnold S. Leonard, Daniel A. Saltzman, Janet L. Schottel
Journal of Drug Targeting.2021; 29(4): 430. CrossRef
A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer
Hyehyun Jeong, Yong Sang Hong, Jeong Eun Kim, Hyeong-Seok Lim, Joong Bae Ahn, Sang Joon Shin, Young Suk Park, Seung Tae Kim, Sae-Won Han, Tae-You Kim, Tae Won Kim
Investigational New Drugs.2021; 39(5): 1335. CrossRef
Application of triazoles as bioisosteres and linkers in the development of microtubule targeting agents
M. Shaheer Malik, Saleh A. Ahmed, Ismail I. Althagafi, Mohammed Azam Ansari, Ahmed Kamal
RSC Medicinal Chemistry.2020; 11(3): 327. CrossRef
Tumor regression and potentiation of polymeric vascular disrupting therapy through reprogramming of a hypoxia microenvironment with temsirolimus
Haiyang Yu, Na Shen, Yanli Bao, Li Chen, Zhaohui Tang
Biomaterials Science.2020; 8(1): 325. CrossRef
Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors
Hark Kyun Kim, Jeong Won Kang, Young‐Whan Park, Jung Young Kim, Minchae Kim, Soo Jin Kim, Se‐mi Kim, Keun Ho Ryu, Seonghae Yoon, Yun Kim, Joo‐Youn Cho, Keun Seok Lee, Tak Yun, Kiwon Kim, Mi Hyang Kwak, Tae‐Sung Kim, Jinsoo Chung, Joong‐Won Park
Pharmacology Research & Perspectives.2020;[Epub] CrossRef
Revolutionizing the landscape of colorectal cancer treatment: The potential role of immune checkpoint inhibitors
Mai F. Tolba
International Journal of Cancer.2020; 147(11): 2996. CrossRef
Discovery of tertiary amide derivatives incorporating benzothiazole moiety as anti-gastric cancer agents in vitro via inhibiting tubulin polymerization and activating the Hippo signaling pathway
Jian Song, Qiu-Lei Gao, Bo-Wen Wu, Ting Zhu, Xin-Xin Cui, Cheng-Jun Jin, Shu-Yu Wang, Sheng-Hui Wang, Dong-Jun Fu, Hong-Min Liu, Sai-Yang Zhang, Yan-Bing Zhang, Yong-Chun Li
European Journal of Medicinal Chemistry.2020; 203: 112618. CrossRef
Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma
Min-Young Kim, Jung-Young Shin, Jeong-Oh Kim, Kyoung-Hwa Son, Yeon Sil Kim, Chan Kwon Jung, Jin-Hyoung Kang
BMC Cancer.2020;[Epub] CrossRef
Discovery and optimization of 3,4,5-trimethoxyphenyl substituted triazolylthioacetamides as potent tubulin polymerization inhibitors
Fang Yang, Cai-Ping He, Peng-Cheng Diao, Kwon Ho Hong, Jin-Jun Rao, Pei-Liang Zhao
Bioorganic & Medicinal Chemistry Letters.2019; 29(1): 22. CrossRef
Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics
Jason H. Gill, Kimberly L. Rockley, Carol De Santis, Asma K. Mohamed
Pharmacology & Therapeutics.2019; 202: 18. CrossRef
Combretastatin A4 Nanoparticles Combined with Hypoxia-Sensitive Imiquimod: A New Paradigm for the Modulation of Host Immunological Responses during Cancer Treatment
Na Shen, Jing Wu, Chenguang Yang, Haiyang Yu, Shengcai Yang, Tete Li, Jingtao Chen, Zhaohui Tang, Xuesi Chen
Nano Letters.2019; 19(11): 8021. CrossRef
Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site
Ling Li, Sibo Jiang, Xiaoxun Li, Yao Liu, Jing Su, Jianjun Chen
European Journal of Medicinal Chemistry.2018; 151: 482. CrossRef
Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
Ryszard Smolarczyk, Tomasz Cichoń, Ewelina Pilny, Magdalena Jarosz-Biej, Aleksandra Poczkaj, Natalia Kułach, Stanisław Szala
Scientific Reports.2018;[Epub] CrossRef
Chemoembolization with Vascular Disrupting Agent CKD-516 Dissolved in Ethiodized Oil in Combination with Doxorubicin: A VX2 Tumor Model Study
In Joon Lee, Myungsu Lee, Soo Jin Kim, You Kyung Kim, Jong Yun Won, Jin Wook Chung
Journal of Vascular and Interventional Radiology.2018; 29(8): 1078. CrossRef
Enhanced efficacy of radiofrequency ablation for hepatocellular carcinoma using a novel vascular disrupting agent, CKD-516
Su Jung Ham, YoonSeok Choi, Seul-I Lee, Jinil Kim, Young Il Kim, Jin Wook Chung, Kyung Won Kim
Hepatology International.2017; 11(5): 446. CrossRef
Early investigational tubulin inhibitors as novel cancer therapeutics
Kunal Nepali, Ritu Ojha, Hsueh-Yun Lee, Jing-Ping Liou
Expert Opinion on Investigational Drugs.2016; 25(8): 917. CrossRef
Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth
María-Jesús Pérez-Pérez, Eva-María Priego, Oskía Bueno, Maria Solange Martins, María-Dolores Canela, Sandra Liekens
Journal of Medicinal Chemistry.2016; 59(19): 8685. CrossRef
Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis
Souvik Banerjee, Dong-Jin Hwang, Wei Li, Duane Miller
Molecules.2016; 21(11): 1468. CrossRef

12,034 View
140 Download
22 Web of Science
22 Crossref

Case Report

A Case of Erdheim-Chester Disease with Asymptomatic Renal Involvement: Hyun Jung Lee, Kyoung Yul Lee, Dong-Yeop Shin, Yun Gyoo Lee, Se Youn Choi, Kyung Chul Moon, Il-Kyu Han, Tae Min Kim; Cancer Res Treat. 2012;44(2):146-150. Published online June 30, 2012; DOI: https://doi.org/10.4143/crt.2012.44.2.146

Abstract PDF PubReader ePub

Erdheim-Chester disease is a rare non-Langerhans-cell histiocytosis involving bones and multiple organs. Its clinical course can vary, from an asymptomatic state to a fatal disease, with renal involvement being a common cause of death. A 41-year-old man presented with a 10-month history of bilateral lower limb pain. Left perirenal soft-tissue infiltration had been found incidentally two years earlier. No progression of the lesion or deterioration of renal function was observed for a period of two years. At admission, plain radiography and magnetic resonance imaging of the patient's lower limbs showed patchy osteosclerosis. Biopsy of the tibia revealed histiocytic infiltration, which was found to be positive for CD68 and negative for CD1a. This report describes an unusual case of Erdheim-Chester disease involving a stationary course of disease with no specific treatment for a long period of time.

Citations

Citations to this article as recorded by

Radiological assessment of extremity bone involvement in Erdheim-Chester disease: a systematic review of case reports
Arash Azhideh, Alireza Pouramini, Sara Haseli, Elahe Abbaspour, Gita Karande, Fatemeh Kafi, Majid Chalian
Skeletal Radiology.2024;[Epub] CrossRef
Erdheim–Chester Disease Involving the Biliary System and Mimicking Immunoglobulin G4-Related Disease: A Case Report
Hyuk Gi Hong, Yong Eun Chung, June Park, Yeo Eun Kim
Journal of the Korean Society of Radiology.2023; 84(3): 757. CrossRef
The role of nuclear medicine in the diagnosis of Erdheim–chester disease. A series of clinical observations
A. S. Krylov, A. D. Ryzhkov, A. A. Odzharova, Ya. A. Shchipakhina, E. E. Stanyakina, A. A. Martinovich, K. D. Ilkaev, A. M. Stroganova, S. L. Dranko, O. P. Bliznyukovv, A. V. Kuzin, P. A. Zeynalova, A. A. Semenova, M. B. Dolgushin
Oncohematology.2020; 15(1): 28. CrossRef
Erdheim–Chester disease. Literature review and clinical case
A. S. Krylov, M. B. Dolgushin, A. D. Ryzhkov, A. A. Odzharova, Ya. A. Shchipakhina, E. A. Sushentsov, O. P. Bliznyukov, S. M. Kaspshik, A. A. Martinovich, A. M. Stroganova, S. L. Dranko, P. A. Zeynalova, T. T. Valiev
Oncohematology.2020; 15(2): 61. CrossRef
Magnetic Resonance Imaging of Perirenal Pathology
James F. Glockner, Christine U. Lee
Canadian Association of Radiologists Journal.2016; 67(2): 149. CrossRef
Erdheim-Chester Disease with Perirenal Masses Containing Macroscopic Fat Tissue
Jonghyun Byeon, Kyung Ah Kim, Seong Su Hwang, Soo Youn Park, Hyun A Kim
Journal of the Korean Society of Radiology.2015; 72(2): 143. CrossRef
Urologic Manifestations of Erdheim-Chester Disease
Daniel A. Yelfimov, Deborah J. Lightner, Matthew K. Tollefson
Urology.2014; 84(1): 218. CrossRef
Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series
Roei D Mazor, Mirra Manevich-Mazor, Anat Kesler, Orna Aizenstein, Iris Eshed, Ronald Jaffe, Yakov Pessach, Ilan Goldberg, Eli Sprecher, Iris Yaish, Alexander Gural, Chezi Ganzel, Yehuda Shoenfeld
BMC Medicine.2014;[Epub] CrossRef
A Rare Cause of Late-Onset Cerebellar Ataxia: Erdheim–Chester Disease
Senthilkumar V. Shanmugam, Madhan Kolappan, Mamta Garg, Winston J. Rennie, Peter Furness, Yusuf A. Rajabally
The Cerebellum.2013; 12(4): 593. CrossRef
Reply to Commentary on "A Case of Erdheim-Chester Disease with Asymptomatic Renal Involvement"
Hyun Jung Lee, Tae Min Kim
Cancer Research and Treatment.2012; 44(4): 280. CrossRef
Commentary on "A Case of Erdheim-Chester Disease with Asymptomatic Renal Involvement"
Gioacchino Li Cavoli
Cancer Research and Treatment.2012; 44(4): 279. CrossRef

15,772 View
78 Download
11 Crossref

First
Prev
Page of 1
Next
Last

Search